Publicis Groupe holds sale talks with private equity investor
Discussions have taken place in recent months.
Investors
Purohit venture arm seeks to back biotech start-ups through ‘service as currency’ model
The women-led investment firm fills a niche between a traditional venture fund and a commercialization agency, founder says.
Five things for pharma marketers to know: Wednesday, January 24, 2018
Novartis sees single-digit growth with new CEO; J&J takes $13.6b charge in the wake of the new tax law; New York City invests in biotech
Five things for pharma marketers to know: Wednesday, January 17, 2018
Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer
Stagwell’s Penn says digital marketing agencies are ‘undervalued’ as he eyes more M&A
The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.
Five things for pharma marketers to know: Friday, January 5, 2018
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Five things for pharma marketers to know: Wednesday, December 20, 2017
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
Five things for pharma marketers to know: Tuesday, December 5, 2017
Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds
Five things for pharma marketers to know: Tuesday, October 31, 2017
Pfizer Q3 revenue driven by Prevnar sales; President Trump’s opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Five things for pharma marketers to know: Monday, June 19, 2017
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
